Trial · NCT03211988
Entinostat Neuroendocrine (NE) Tumor
NCT03211988, Phase 2, Terminated, Antonio Fojo; results first posted 2026-03-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Entinostat Neuroendocrine (NE) Tumor. Trials, record NCT03211988. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03211988
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Entinostat Neuroendocrine (NE) Tumor
- NCT number
- NCT03211988
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Antonio Fojo
- Conditions
- Neuroendocrine Tumors
- Interventions
- Entinostat
- First posted
- 2017-07-11
- Last updated
- 2026-03-02
- Results first posted
- 2026-03-02
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR) | Up to 44 months | Objective response defined as complete response (CR) (Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.) and partial response (PR) (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) and will be determined from each participant's best confirmed response during protocol therapy. Response as evaluated per RECIST 1.1 criteria. |
| Secondary | Duration of Progression-Free Survival (PFS) | Up to 45 months | Time from study enrollment until disease progression or death. |
| Secondary | Duration of Overall Survival (OS) | Up to 45 months | The length of time from either the date of diagnosis or start of treatment that years participants diagnosed with the disease are still alive. |
| Secondary | Duration of Response for Participants Who Achieve Complete Response (CR) or Partial Response (PR) | Up to 4 years | Time from documentation of tumor response to disease progression in participants who achieve CR or PR. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate (ORR) | Up to 44 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Duration of Progression-Free Survival (PFS) | Up to 45 months | days | MEDIAN | |
| SECONDARY | Duration of Overall Survival (OS) | Up to 45 months | days | MEDIAN | |
| SECONDARY | Duration of Response for Participants Who Achieve Complete Response (CR) or Partial Response (PR) | Up to 4 years | Zero analyzed as there were no participants that achieved CR or PR. |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | Entinostat | 0 | Participants | ||
| Duration of Progression-Free Survival (PFS) | Entinostat | 381 | Full Range 232 to 754 | days | |
| Duration of Overall Survival (OS) | Entinostat | 1422 | Full Range 1163 to 1611 | days |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Entinostat | 5 | |
| Overall Study | COMPLETED | Entinostat | 4 | |
| Overall Study | NOT COMPLETED | Entinostat | 1 |
Source ClinicalTrials.gov
Adverse events26
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | Gastrointestinal disorders | Entinostat | 1 | 5 | |
| other | Hypophosphatemia | Metabolism and nutrition disorders | Entinostat | 1 | 5 | |
| other | Hyperkalemia | Metabolism and nutrition disorders | Entinostat | 1 | 5 | |
| other | Vomiting | Gastrointestinal disorders | Entinostat | 3 | 5 | |
| other | Anorexia | Metabolism and nutrition disorders | Entinostat | 2 | 5 | |
| other | Bloating | Gastrointestinal disorders | Entinostat | 1 | 5 | |
| other | Fatigue | General disorders | Entinostat | 3 | 5 | |
| other | Nausea | Gastrointestinal disorders | Entinostat | 4 | 5 | |
| other | Urinary tract pain | Renal and urinary disorders | Entinostat | 1 | 5 | |
| other | Neutrophil count decreased | Investigations | Entinostat | 4 | 5 |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Entinostat | 1 | 5 |
| Total, other adverse events | Entinostat | 5 | 5 |
| Total, serious adverse events | Entinostat | 1 | 5 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38886159 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03211988
GET https://conductscience.org/api/trials/v1/NCT03211988/events?page=2